Nuclea Biotechnologies is a healthcare company dedicated to the development and commercialization of clinical diagnostic assays identifying gene and protein expression profiles characteristic of an individual's tumor or disease. The firm is committed to advancing discovery and validation of clinical test platforms that are predictive of a cancer patient's responsiveness to oncology therapeutics and the likelihood of disease recurrence.
